

LIVER STEATOSIS IN OBESE CHILDREN COURSES WITH ENHANCED INSULIN RESISTANCE AND DYSLIPIDEMIA, WHICH ARE INFLUENCED BY GENDER, PUBERTY, RACE AND BODY FAT DISTRIBUTION.

Gabriel Á. Martos-Moreno^{1,2,3}, Julián Martínez-Villanueva¹, Rocío González-Leal¹, Arturo Mínguez², Sara Sirvent², Guillermo Martínez⁵, Federico Hawkins⁵, Jesús Argente^{1,2,3}

¹Department of Endocrinology, Hospital Infantil Universitario Niño Jesús, IIS La Princesa. ²Universidad Autónoma de Madrid ³CIBERobn, Instituto de Salud Carlos III; Madrid, Spain.

⁴Department of Radiology, Hospital Infantil Universitario Niño Jesús, IIS La Princesa.; ⁵Department of Endocrinology, Hospital Universitario 12 de Octubre. Universidad Complutense de Madrid.

Introduction:

- Obesity, insulin resistance (IR) and dyslipidemia are major predisposing factor for the development of liver steatosis (LS), although severity of LS is not exclusively related to the degree of overweight.
- The observed increase in obesity prevalence and severity in children in the past decades has turned it into the main cause of LS in children and adolescents, even above drug side effects or biliary diseases.

The authors have nothing to disclose

Objective:


- To investigate the differential features of patients diagnosed with obesity associated LS (as diagnosed by ultrasonography).

Patients and methods:

- We retrospectively studied 88 obese children with LS (**LS-OB**: mean age 12.07 ± 2.81 years and BMI 4.60 ± 2.30 SDS) and 88 obese children without LS (**no-LS-OB**: mean age 11.91 ± 2.76 years and BMI 4.46 ± 3.43 SDS).
- Both groups were age, BMI, gender, race and puberty matched and their composition was: 71.6% males / 28.4% females; 56.5% Caucasians / 41.2% Latinos; 60.2% pubertal/39.8% prepubertal.
- The analyzed variables included:** **Anthropometric:** Body mass index (BMI-SDS). **Metabolic:** Baseline and after OGTT (1.75 g/kg, maximum 75g) glucose and insulin levels and derived indexes (HOMA, WBISI); HbA1c; lipid profile, apoprotein-A1 and B, liver enzymes (AST/ALT) and uric acid in both groups. Additionally, body composition measured by Dual energy X-ray absorptiometry (DXA) and abdominal fat distribution measured by magnetic resonance imaging (MRI) were studied in 27 **LS-OB**.

Results:

- Obesity associated LS was mainly **diffuse** (97.7%, only 4 cases of focal LS) and **mild** (Stage I / III, 65.9%). **LS-OB** showed a prevalence of IR of 65.8% (as estimated by insulin levels in the OGTT); mean HOMA 4.62 ± 3.36 and HbA1c levels were >5.7% in 35.9% of them. In **LS-OB**, the prevalence rate for **dyslipidemia** (low HDL, high LDL, VLDL or triglycerides), **25-OH-vitamin D insufficiency** (< 20 ng/ml) and IR were **30%, 79.4% y 65.8%**, respectively.
- LS-OB** showed higher AST/ALT (p<0.001), insulin/HOMA (p<0.05) and triglycerides/VLDL (p<0.01) than **no-LS-OB** (**FIGURE**).
- Among diffuse **OB-LS**, those **moderate-severe** (Stage II-III; 31.8%) associated **lower WBISI** and **HDL levels** (p < 0.05) and **higher AST** (p < 0.05), **ALT** (p < 0.01), **apoprotein-B** (p < 0.05) and **LDL/HDL ratio** (p < 0.05). Their **trunk to lower limb** (DXA) and **visceral/subcutaneous** (RM) fat ratios were **higher** (p < 0.05) than those in patients with mild LS (Stage I, 65.9%) (**TABLE**).
- Among **LS-OB**, **increased serum liver enzyme levels** (AST/ALT) was observed in **40.5%** patients (lower levels in prepubertals and females [p < 0.05]). Compared to those patients with LS but without increased serum liver enzymes, they showed **higher glucose** and **insulin at 30 minutes** in the OGTT (p<0.05 and p<0.01), **cholesterol**, **apoprotein-B**, **cholesterol/HDL** and **LDL/HDL-ratios** (p<0.05) and **higher trunk to lower limb** (DXA) and **visceral/subcutaneous** (RM) fat ratios (p<0.05).
- Latinos** showed higher rates of **dyslipidemia** (decrease in HDL and increased LDL/HDL ratio), **25-OH-vitamina D insufficiency** (p < 0.05 and p<0.001, respectively) and **acantosis nigricans** (p < 0.01) (**TABLE**).



Comparison according to ethnic background		Latino	Caucasian	Significance level
Chronological age in years (mean ± SDS)		11.57 ± 2.90	12.61 ± 2.70	NS
SEX (%)	FEMALE	37	25	NS
	MALE	63	75	
PUBERTY (%)	Prepubertal	35.3	39.6	NS
	Pubertal	64.7	60.4	
BMI-SDS		4.14 ± 1.59	4.88 ± 2.62	NS
HDL (mg/dl)		38.55 ± 11.20	44.63 ± 11.06	p < 0.05
LDL/HDL ratio		2.78 ± 0.96	2.33 ± 0.94	p < 0.05
25-OH-vitamin D (ng/ml)		12.30 ± 4.96	22.36 ± 7.71	p < 0.001
Comparison according to LS severity (ultrasonography)		Moderate-Severe (Stages II-III)	Mild (Stage I)	Significance level
WBISI		0.78 ± 0.32	1.10 ± 0.64	p < 0.05
HDL (mg/dl)		38.10 ± 10.00	44.59 ± 11.24	p < 0.05
LDL/HDL ratio		2.82 ± 1.03	2.32 ± 0.90	p < 0.05
AST (U/l)		42.61 ± 19.22	33.72 ± 14.62	p < 0.05
ALT (U/l)		60.93 ± 35.03	38.59 ± 24.39	p < 0.01
Apoprotein-B (mg/dl)		90.02 ± 26.31	77.39 ± 17.02	p < 0.05
Trunk to lower limb fat ratio (DXA)		1.58 ± 0.33	1.32 ± 0.17	p < 0.05
Visceral to subcutaneous fat ratio (MRI)		0.28 ± 0.08	0.22 ± 0.05	p < 0.05

Abbreviations: BMI: Body mass index; HDL: high density lipoprotein; LDL: low density lipoprotein; LS: Liver steatosis; NS: non significant; VLDL: Very low density lipoprotein; WBISI: Whole body insulin sensitivity index.

Conclusions:

- Liver steatosis in obese children courses with enhanced insulin resistance and dyslipidemia.
- Severe obesity associated liver steatosis is associated with greater visceral adiposity and metabolic impairment, which are also influenced by race, sex and pubertal stage.

Acknowledgements: This study has been funded by PI13-02195 (Fondo de Investigación Sanitaria) and CIBERobn and FEDER funds.